Hyperinsulinemia Predisposes to NAFLD
Overview
Affiliations
Metabolic syndrome contributes to pathogenesis of Type-2 diabetes and CAD. Insulin Resistance is the key factor of metabolic syndrome implicated in development of Non Alcoholic Fatty Liver Disease (NAFLD). In present study we have investigated the prevalence of NAFLD in metabolic syndrome and contribution of metabolic risk factors in causation of NAFLD in non-diabetic North Indian male population. The study was conducted on 495 non-diabetic, nonalcoholic subjects (age 30-65 years). Metabolic Syndrome was assessed by using ATP III and ADA (2005) criteria. Anthropometric factors-Waist circumference and blood pressure were measured. Fasting serum samples were analyzed for Glucose, Triglycerides, Cholesterol and its fractions, Insulin, Alanine transaminase, Aspartate transaminase, Gamma glutamyl transferase and free fatty acids. Insulin resistance was estimated by Homeostasis Model and Insulin sensitivity by QUICKI Index. Liver ultrasonographic scanning was used for assessing fatty liver. The prevalence of metabolic syndrome and NAFLD was 24% and 14.8% respectively in non-alcoholic population and 27% of metabolic syndrome had NAFLD which was associated with hyperinsulinemia, insulin resistance, insulin insensitivity along with elevated levels of waist circumference, blood pressure, triglyceride, FFA and decreased HDL-Cholesterol. The prevalence of NAFLD increased with insulin resistance and clustering of metabolic risk factors.
Motamedi A, Alizadeh S, Osati S, Raeisi T, Homayounfar R Public Health Nutr. 2024; 27(1):e182.
PMID: 39324343 PMC: 11504692. DOI: 10.1017/S1368980024001149.
Fatahi S, Sohouli M, Rayi A, Teymoori F, Shidfar F Gastroenterol Hepatol Bed Bench. 2021; 14(3):221-228.
PMID: 34221261 PMC: 8245830.
Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.
Kothari S, Dhami-Shah H, Shah S J Clin Exp Hepatol. 2020; 9(6):723-730.
PMID: 31889754 PMC: 6926203. DOI: 10.1016/j.jceh.2019.06.003.
The value of neck circumference (NC) as a predictor of non-alcoholic fatty liver disease (NAFLD).
Hu Y, Chen J, Yang L, Chen P, Li J, Chen L J Clin Transl Endocrinol. 2017; 1(4):133-139.
PMID: 29159094 PMC: 5685024. DOI: 10.1016/j.jcte.2014.07.001.
Goyal R, Kumar A, Singhai M Indian J Clin Biochem. 2014; 29(3):362-6.
PMID: 24966487 PMC: 4062672. DOI: 10.1007/s12291-013-0366-4.